Armistice Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Armistice Capital’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-39,000	Closed	-$2.67M	–	86
2019 Q1	$2.67M	Sell	39,000 -1,000	-3%	-$64.2K	0.15%	63
2018 Q4	$2.11M	Buy	+40,000	New	+$2.55M	0.16%	56

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital's SRRA Position: Q2 2019 in Review

Armistice Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2019, closing a stake of 39,000 shares — an estimated $2.67M sold.

Armistice Capital first reported a position in SRRA in Q4 2018 and held it in 2 quarters. The position peaked at $2.67M in Q1 2019. 49 funds tracked by Wall St. Rank hold SRRA as of Q2 2019.

Armistice Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Armistice Capital sold 39,000 Sierra Oncology, Inc. Common Stock shares in Q2 2019, an estimated $2.67M.
Armistice Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
Armistice Capital's Sierra Oncology, Inc. Common Stock position peaked at $2.67M in Q1 2019.
49 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2019.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.